Market research
CNTX Context Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 32M
- P/E ratio
- Not available
- Analyst target
- 4.2511
- Dividend yield
- Not available
- Beta
- 1.69
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US21077P1084
- Market cap
- 32M
- P/E ratio
- Not available
- Analyst target
- 4.2511
- Dividend yield
- Not available
- Beta
- 1.69
About
About Context Therapeutics Inc
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the CNTX discussion.
No comments yet
Start a focused discussion about CNTX.